The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
HT - good point & did think similar ( or hope )
Cyrox - that got a chuckle 👍
Closing price 1.59 - 1%+
Vol 5.4 million - low
Let’s see what coming weeks / months bring
Only 1% down on an RNS.
If there was something exciting to say, they would have said it by now. News will come when something is actually done by hemo. Whether the trials being launched will affect the share price is anyone's guess since there is zero interest in buying here. This was once the stock of the century with people (including me) predicting 10p+. Until we get a licence agreement or some funding guarantee, this is a tough risky buy sadly. I just wish a big pharma would get some pocket change and buy the company and delive
End of year results were 3 days earlier than usual....is another RNS coming very soon ??
i gey shouted down for being negative but everything i have said has nbeen so true to all you rampers , its a panicking **** show burning cash at a rate no news of patients as i said we gambled and lost they will look for new funding. sp will be no good to low so will have to look to partner on the cheap. cant go against the science and ideas but in reality not happening is it .. fact ....
2x 500k buys just gone through
It will come I'm sure but maybe for us older investors , it maybe a bit too long to wait .
A lot of disgruntled investors on here of late
Stock price has been stuck between 1.55 @ 1.7 for weeks since placement
Volume is very low of late
3 million today
The stock certainly won’t motor north with thin volume , & purely trading water until news arrives .
However will motor north when further news on clinical is announced or a pharma deal with help from Prevail , imo
To note -
Stock on loan / shorts
Current 4.3 million
a 200 k short was opened Tuesday , I would guess a chancer hoping for bad news within the results
& a 4.2 million short was opened 2 days after placement news @1.62
So i am sceptical on any stock & any forums with negativity been posted with recent shorts opened , very risky in Hemo’s current position imo
Hemo are clinical & working with Prevail on CAR T
With CBR & CDX cooking
Good products will attract financial pharmas once news is confirmed. Imo
Thats what im trying to allude to, 1 patient, which shows promise, could be an opening that the Vlad needs to secure substantial funding? So, perhaps knowledge and lead time of the first person sees the stock stabalise in terms of SP?
And HT - Im not deramping, I think the SP says it all, so why dont you just have a reality check and understand the SP has got nothing to do with adhoc posts I may make! Silly boy.
Oh eff off Guinness wit your deramping.
In truth I have no idea about the financial side - but if they have developed what I think they have then the financial side will take care of itself IMO. It is plausible that a deal could be done at any time but they will need to show efficacy before the big deals are struck - that is the gamble. A whiff of efficacy and this is worth many multiples of the current market cap whether that be 1 patient or 3 I dont know.
Oh eff Guinness wit your deramping.
Nice to read that the Chairman thinks all is ok"Remember his INFLECTION point of the company "that was I 2021!!! 😆
By being "enough", I mean enough to raise, not to go to Phase II!
What do you think the the cash position is Haywain? Maybe £3m?
Do you think 1 person goes to trial, and if the results are favourable from 1, they raise or do a JV from that? Would 1 be enough? Im thinking probably not but Im not an industry expert.
Sir Marc Feldmann "In summary, we should say that the considerable potential breadth and versatility of CBR has become increasingly evident over the past fifteen months, and evidence of its practical viability has been considerably established. It is not too much to say that CBR, which we always considered to have great potential, can now be seen as possibly revolutionary, now that its widespread probable applicability to difficult or presently untreatable conditions is being established in multiple preclinical studies" - I am here to see Hemo-CAR-T and CBR come to fruition, however long that takes.
HT - Because I follow the company and see how disppointing things are for the science, the research they team has done, and for what? To be under severe funding pressure. It is a shame, thats all HT. Nothing else.
Additionally, where is JHFH? He who said so many things about a clin trial company being no less than £100m CAP > I got slated for "deramping", but JFH has been ramping all along, even if unknowingly so! Where is HedgeBackwards?
They aint here are they! Theyve either lost lots, down lots, or made lots! You decide.
You are not a hemo investor Guinness...why are you here.
As an investor, where is the value now in HEMO, in terms of science versus funding? I am not in, and unlike previous times, I don't see what the short and medium term bring for HEMO. The company is marked down so much that raising again will be 1.5p or even 1.2p.
The BoD has allowed too many trading opportunities for a product that it potentially life saving. I go back to what I said previously, I think they're looking for an exit to go private.
Unless a JV with a global pharma is announced, Vlad seems to have played his deck on LSE.
Im sorry, but with vlads ego, nothing is too far fetched. If he can carry on his way, then he would do it i reckon. It will be on X first though.. in code
Mattpr .. I think that is too far fetched. This company will succeed but only because the science will make it succeed. The problem is that most investors will be gone by then and someone will pick up the science for a cheap amount when the company if managed well would have been worth £100m - £500m.
if only Vlad had stopped pumping with silly RNSs and actually delivered CART on time ... his only claim to fame is that he has done whatever he has done cheaply. Not great for the CEO of game changing cancer drugs
Yes there seems to be nothing on any trials taking place.
Once confirmation of trials has begun/completed then confidence will return back
Well they won't be joining Nasdaq a this made me laugh when I googled it
"the Nasdaq won't allow just any company to be traded on its exchange. Only companies with a solid history and top-notch management behind them are considered."
At least we can boast we invested in the only pharma company to bomb after going clinical i suppose 😀